Gene Signatures Show Why Boys are Predisposed to Asthma
New study highlights why males are more prone to respiratory disorders than females, especially during early life.
CONCLUSIONS: These findings show that a considerable proportion of patients with severe asthma remain uncontrolled and are not eligible for any of the available biological treatments. This underlines the need for therapeutic innovations in this disease. PMID: 30429093 [PubMed - as supplied by publisher]
Conclusions: In the CAR registry, patients with SAA treated with omalizumab showed a significant positive effect of anti-IgE therapy not only on the asthma control, but also on allergic comorbidities. PMID: 30429711 [PubMed]
Conclusions: These results provides further evidence that therapy with omalizumab improves spiromtric parameters in severe asthma. PMID: 30429708 [PubMed]
Conclusions: Our results suggest that IL-25 is particularly associated with severe asthma. The relationship between IL-25 and neutrophilic airway inflammation suggests the pleiotropic role of IL-25 in the immune response in this disease. PMID: 30429702 [PubMed]
Authors: Namysłowski A, Samoliński BK, Lipiec A, Zieliński W, Sybilski AJ, Walkiewicz A, Samel-Kowalik P, Samoliński K, Raciborski F Abstract Introduction: Specific immunoglobulins E (sIgE) are important parameters to estimate severity of allergic diseases. Aim: To determine the influence of allergy risk factors on the concentration of specific IgE antibodies in serum. Material and methods: The concentration of sIgE antibodies against allergens Dermatophagoides pteronyssinus, cat dander, timothy grass, Alternaria alternata were determined in serum of 4077 respondents randomly selected from 9 regions (EC...
CONCLUSIONS: TSLP might promote asthmatic airway remodeling via p38 MAPK-STAT3 axis activation and the crosstalk between airway epithelial cells and fibroblasts could aggravate remodeling. Blockade of p38 could alleviate airway remodeling which might provide a new therapeutic target for asthma. PMID: 30428724 [PubMed - as supplied by publisher]
Vapotherm said today it closed its initial public offering, raising a total $64.4 million in gross proceeds. The Exeter, N.H.-based company developed the Precision Flow line of devices to provide high-velocity heated, humidified and oxygenated air to treat patients with conditions such as pneumonia, chronic obstructive pulmonary disease, asthma and heart failure. Some 1,200 of the devices have been sold in the U.S., mostly into hospital ICUs, the company said. Vapotherm said it floated 4.6 million shares of its common stock at $14 per share, and that the offering featured a fully exercised underwriter’s option to pur...